INKT: MiNK Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 26.89
Enterprise Value ($M) 21.98
Book Value ($M) -16.58
Book Value / Share -0.42
Price / Book -1.62
NCAV ($M) -17.43
NCAV / Share -0.44
Price / NCAV -1.54

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.85
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.93
Current Ratio 0.93

Balance Sheet (mrq) ($M)
Current Assets 9.47
Assets 10.32
Liabilities 26.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
05-22 13G Gkcc, Llc 11.79
02-14 13D Armen Garo H 9.68

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-25 3,592 55,405 6.48
2024-11-22 7,385 32,903 22.44
2024-11-21 3,649 23,865 15.29
2024-11-20 2,154 21,641 9.95

(click for more detail)

Similar Companies
IMNN – Imunon, Inc. IMTX – Immatics N.V.
INDP – Indaptus Therapeutics, Inc. INM – InMed Pharmaceuticals Inc.
INMB – INmune Bio, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.